Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide for obesity in adults with end-stage kidney disease on haemodialysis
ACTRN12624000665538Phase 2Recruiting
- Sponsor
- St Vincent's Hospital Melbourne
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tirzepatide in obesity, sponsored by St Vincent's Hospital Melbourne. Primary endpoint: Proportion of participants using tirzepatide 15 mg weekly at 24 weeks. Started Oct 2024; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on ACTRN12624000665538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000665538.